US FDA Approves AbbVie Parkinson Drug
The US Food and Drug Administration has approved AbbVie treatment tavapadon for adults with Parkinson disease. The once-a-day pill will be sold under the brand name Juvmo following late-stage trial success.
Xurve View
Perspectivas:
Xurve View
United States health regulators approved ABBVIE INC's once-a-day pill Juvmo for Parkinson's disease on Friday afternoon. The treatment targets over 11 million patients worldwide who suffer from the progressive brain condition. The approval provides a key milestone for AbbVie's neurology portfolio following its acquisition of Cerevel Therapeutics.
